Company news
Tevogen Bio Holdings Inc. news in 2025
Tevogen Bio Holdings Inc.'s news releases, calls and decks from 2025, newest first.
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
December 22, 2025
Tevogen CEO Donates Personal Shares to Support Local Fire Department
December 19, 2025
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
December 11, 2025
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
December 9, 2025
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
December 8, 2025
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
November 14, 2025
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
November 5, 2025
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
November 3, 2025
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
October 29, 2025
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
October 15, 2025
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
September 25, 2025
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
September 23, 2025
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
September 19, 2025
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10, 2025
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 9, 2025
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 8, 2025
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
September 4, 2025
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
September 3, 2025
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
August 27, 2025
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
August 26, 2025
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 25, 2025
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
August 19, 2025
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
August 19, 2025
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
August 18, 2025
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
August 18, 2025
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
August 14, 2025
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 13, 2025
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
August 11, 2025
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
August 11, 2025
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
August 11, 2025
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 11, 2025
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 8, 2025
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
August 7, 2025
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 6, 2025
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 5, 2025
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 1, 2025
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
August 1, 2025
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
July 30, 2025
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
July 28, 2025
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
July 18, 2025
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
July 17, 2025
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
July 16, 2025
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
July 14, 2025
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
July 10, 2025
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
June 30, 2025
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
June 18, 2025
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
June 9, 2025
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
May 30, 2025
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
May 23, 2025
Decks in 2025
- Investor Presentation (June 2025)
Investor deck · 34 slides · June 2025